Part 1: Long-Term Outcomes of Adjuvant CDK4/6 Inhibitors in HR-Positive/HER2-Negative Early Breast Cancer
Impossibile aggiungere al carrello
Rimozione dalla Lista desideri non riuscita.
Non è stato possibile aggiungere il titolo alla Libreria
Non è stato possibile seguire il Podcast
Esecuzione del comando Non seguire più non riuscita
Part 1: Long-Term Outcomes of Adjuvant CDK4/6 Inhibitors in HR-Positive/HER2-Negative Early Breast Cancer
-
Letto da:
-
Di:
A proposito di questo titolo
We are pleased to present Part 1 of an exclusive podcast, Emerging Data and Trends in HR-Positive/HER2-Negative Breast Cancer.
Part 1 of this series provides peer-to-peer physician perspectives on emerging data in the adjuvant treatment of hormone receptor (HR)-positive/HER2-negative early breast cancer.
Topics include:
- The role of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors in the treatment of early-stage HR-positive/HER2-negative breast cancer
- Long-term outcomes of CDK4/6 inhibitors including new 7-year data from the monarchE trial and 5-year data from the NATALEE trial
Discussants:
Neil M. Iyengar, MD
Director, Survivorship Services, Winship Cancer Institute of Emory University
Co-Director, Breast Medical Oncology, Department of Hematology and Medical Oncology
Associate Professor, Department of Hematology and Medical Oncology
Emory University School of Medicine
Atlanta, GA
Seth Wander, MD, PhD
Director, Precision Medicine, Termeer Center for Targeted Therapies
Director, Translational Research, Breast Oncology Program
Assistant Professor of Medicine, Harvard Medical School
Massachusetts General Hospital
Boston, MA
Sponsored by Lilly